EverSource Wealth Advisors LLC Has $76,000 Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

EverSource Wealth Advisors LLC lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 32.1% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,698 shares of the biopharmaceutical company’s stock after buying an additional 655 shares during the period. EverSource Wealth Advisors LLC’s holdings in Royalty Pharma were worth $76,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc boosted its stake in shares of Royalty Pharma by 5,215.0% during the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,043 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Royalty Pharma during the 2nd quarter worth approximately $32,000. Fidelis Capital Partners LLC bought a new stake in Royalty Pharma in the first quarter valued at $46,000. GAMMA Investing LLC raised its stake in Royalty Pharma by 172.5% during the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,037 shares during the period. Finally, Parallel Advisors LLC grew its position in Royalty Pharma by 62.7% in the 4th quarter. Parallel Advisors LLC now owns 2,882 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 1,111 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Trading Up 0.1 %

Royalty Pharma stock opened at $28.21 on Friday. Royalty Pharma plc has a 12 month low of $25.20 and a 12 month high of $31.66. The business’s fifty day simple moving average is $28.01 and its two-hundred day simple moving average is $27.93. The company has a market capitalization of $16.74 billion, a price-to-earnings ratio of 21.05, a price-to-earnings-growth ratio of 4.09 and a beta of 0.46. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The business had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.83 million. During the same period in the previous year, the business earned $0.85 EPS. As a group, equities analysts predict that Royalty Pharma plc will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Friday, August 16th were paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 2.98%. The ex-dividend date of this dividend was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on RPRX shares. The Goldman Sachs Group increased their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Morgan Stanley increased their price objective on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Finally, UBS Group downgraded shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target for the company. in a report on Monday, June 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.